Stock Comparison

JNJ vs TMDX

Johnson & Johnson vs Transmedics Group Inc

The Verdict

TMDX takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

TMDX

Transmedics Group Inc

6.8

out of 10

Solid Pick

Head-to-Head

$557.1B

Market Cap

$2.5B

26.5

P/E Ratio

14.8

21.8%

Profit Margin

27.0%

26.3%

Return on Equity

41.9%

0.6

Debt-to-Equity

1.1

Conservative

Overall Risk

Aggressive

1.0

DVR Score

6.8

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

TMDX6.8/10

Transmedics (TMDX) maintains a compelling long-term thesis driven by its market-leading Organ Care System (OCS) and strategic expansion into integrated organ logistics (NOCS). The Q1 2026 results confirmed robust +21.2% YoY revenue growth, and FY2026 guidance was reiterated, reflecting continued management confidence in the NOCS rollout. However, the Q1 EPS of $0.30 significantly missed consensus ...

Full TMDX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.